Quality Of Life While Receiving Faslodex

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325 ·Status: COMPLETED ·Phase: PHASE3

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer

NCT00878930 ·Status: COMPLETED

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

NCT00944918 ·Status: COMPLETED ·Phase: PHASE3

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

NCT01602380 ·Status: COMPLETED ·Phase: PHASE3

Faslodex Post Marketing Surveillance

NCT00860561 ·Status: COMPLETED

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer

NCT01171417 ·Status: COMPLETED

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

NCT00259090 ·Status: COMPLETED ·Phase: PHASE2

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

NCT00241449 ·Status: COMPLETED ·Phase: PHASE3

Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors

NCT00253422 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Sexual Quality of Life for Breast Cancer

NCT04200001 ·Status: COMPLETED

Efficacy and Safety of 500mg of Fulvestrant

NCT00585507 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

NCT00543127 ·Status: TERMINATED ·Phase: PHASE3

Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

NCT00692289 ·Status: COMPLETED

Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer

NCT02000193 ·Status: UNKNOWN ·Phase: PHASE2

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

NCT03236974 ·Status: COMPLETED ·Phase: PHASE1

Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment

NCT01144572 ·Status: COMPLETED

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

NCT00357110 ·Status: COMPLETED ·Phase: PHASE2

Sexual Quality of Life in Women During the First Year of Adjuvant Hormonal Treatment for Breast Cancer.

NCT04539587 ·Status: COMPLETED

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

NCT05439499 ·Status: UNKNOWN ·Phase: PHASE3

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

NCT01425294 ·Status: TERMINATED

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

NCT00126464 ·Status: UNKNOWN ·Phase: NA

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

NCT00754325 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

NCT02374099 ·Status: TERMINATED ·Phase: PHASE2

Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence

NCT01081509 ·Status: COMPLETED